Community Epidemiology and Typology of Third-generation Cephalosporins Resistant Enterobacteriaceae in Reunion Island

Community Epidemiology and Typology of Third-generation Cephalosporins Resistant Enterobacteriaceae (Prevalence, Resistance Mechanisms and Risk Factors) in Reunion Island

NCT03226314•Centre Hospitalier Universitaire de la Réunion

View on ClinicalTrials.gov

Summary

In its report dated april 2014, World Health Organization confirms antibiotic resistance dissemination in all parts of the world, in hospitals and in community and worries about a possible comeback to a pre-antibiotic era during the 21st century. For the last 15 years, third-generation cephalosporins resistant enterobacteriaceae (3GCREB) prevalence is continuously increasing. Community 3GCREB prevalence has not been studied whereas several observations made in Reunion Island hospital suggest a diffusion in community. In this situation of world-wide and regional extension of bacterial resistance, the investigator offers to study bacterial resistance to antibiotic in Reunion Island community.

Detailed Description

The investigator is focused on E. coli species exhibiting BLSE or metallo-betalactamases production that could be encountered du to the increasing level of migratory flow in Reunion Island. Fecal sample collection will be used for further investigations on bacterial typology.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Patients:
•aged over 18 years old
•admitted in emergency ward or intensive care of the university hospital of Reunion Island
•who received the patient information notice and who gave their consent
•who have a stool sample performed in the 48 hours following admission
•who understand and can read French

Exclusion Criteria

•Patients:
•transferred from a short-term, middle-term or long-term stay health facility
•who have a stool sample performed more than 48 hours following admission.

Locations (1)

Chu Reunion Island

Saint-Pierre, Reunion Island, Reunion

Key Dates

Start Date

November 21, 2017

Primary Completion Date

December 1, 2018

Completion Date

June 30, 2019

Last Updated

March 7, 2019

Enrollment

500

ACTUAL participants

Conditions

Bacterial Resistance

Interventions

stool sample

PROCEDURE

Antistaphylococcal Betalactam and Emergence of Resistance

NCT05939479

Bacterial ResistanceMethicillin-Sensitive Staphylococcus Aureus Infection

View study

COMPLETEDEARLY_PHASE1

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

NCT01878643

Respiratory InfectionBacterial Resistance+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions